Phenylephrine induces endogenous noradrenaline release in the rat vas deferens through nitric oxide synthase pathway

Pharmacol Toxicol. 2003 Oct;93(4):191-6. doi: 10.1034/j.1600-0773.2003.930407.x.

Abstract

We have previously observed that in the rat vas deferens nitric oxide synthase pathway potentiated phenylephrine-induced contractility raising the possibility of a facilitatory role on neurotransmission by nitric oxide. To confirm this hypothesis we studied the effect of phenylephrine on the concentration response curves obtained in preparations from reserpine-treated rats in the absence and presence of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). The endogenous noradrenaline released by normal preparations (without reserpine) was measured in the perfusion fluid of preparations stimulated with phenylephrine, in the absence and presence of L-NMMA, L-NMMA + the nitric oxide donor 3-morpholinosydnonimine hydrochloride (SIN-1), the alpha1-adrenoceptor antagonist prazosin and the blocker of noradrenaline carrier desipramine. The phenylephrine-induced noradrenaline release in a calcium-free medium was also measured. L-NMMA decreased the Emax of phenylephrine concentration response curves obtained in preparations from normal (reserpine-untreated) but not from reserpine-treated rats. In the perfusion fluid of preparations incubated with phenylephrine, a concentration-dependent increase of noradrenaline was observed which was reversed by L-NMMA and restored when SIN-1 was added together with the nitric oxide synthase inhibitor. The concentration-dependent phenylephrine-induced noradrenaline increase was not modified by desipramine but was abolished by 10 microM prazosin. In calcium-free medium, phenylephrine failed to increase the noradrenaline concentration. These results suggest that in the rat vas deferens, nitric oxide pathway potentiates the phenylephrine-induced contractility through a mechanism which involves calcium-dependent release of endogenous noradrenaline and seems to depend, at least partially on the activation of alpha1-adrenoceptors.

Publication types

  • Comparative Study

MeSH terms

  • Adrenergic Uptake Inhibitors / pharmacology
  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic alpha-Antagonists / pharmacology
  • Animals
  • Desipramine / pharmacology
  • In Vitro Techniques
  • Male
  • Muscle Relaxation / drug effects
  • Muscle, Smooth, Vascular / drug effects*
  • Muscle, Smooth, Vascular / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / metabolism*
  • Nitric Oxide Synthase Type II
  • Norepinephrine / biosynthesis*
  • Phenylephrine / pharmacology*
  • Prazosin / pharmacology
  • Rats
  • Rats, Wistar
  • Receptors, Adrenergic, alpha-1 / metabolism
  • Vas Deferens / drug effects*
  • Vas Deferens / enzymology
  • Vas Deferens / metabolism
  • Vasoconstrictor Agents / pharmacology*
  • omega-N-Methylarginine / pharmacology

Substances

  • Adrenergic Uptake Inhibitors
  • Adrenergic alpha-1 Receptor Agonists
  • Adrenergic alpha-Antagonists
  • Receptors, Adrenergic, alpha-1
  • Vasoconstrictor Agents
  • Phenylephrine
  • omega-N-Methylarginine
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • Desipramine
  • NG-Nitroarginine Methyl Ester
  • Norepinephrine
  • Prazosin